To this end, our data reveal that the BCR-ABL1 inhibitor imatinib reduces BCL-XL and p-ERK and sensitizes CML cells to the lethal consequences of hydroxyurea-induced replication stress. Here, MAPK1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.